Zacks Research Has Negative Outlook for RDY Q3 Earnings

Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Zacks Research decreased their Q3 2026 earnings estimates for shares of Dr. Reddy's Laboratories in a research report issued to clients and investors on Friday, May 30th. Zacks Research analyst R. Department now expects that the company will earn $0.19 per share for the quarter, down from their prior forecast of $0.20. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' FY2026 earnings at $0.77 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.12 EPS, FY2027 earnings at $0.57 EPS and FY2028 earnings at $0.61 EPS.

Separately, Wall Street Zen upgraded Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th.

Dr. Reddy's Laboratories Stock Performance

NYSE:RDY traded down $0.08 during trading hours on Monday, reaching $14.66. 1,240,450 shares of the stock were exchanged, compared to its average volume of 2,020,306. The stock has a market capitalization of $12.24 billion, a P/E ratio of 23.34 and a beta of 0.33. The firm has a 50 day simple moving average of $13.71 and a 200-day simple moving average of $14.01. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories has a 52 week low of $12.26 and a 52 week high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. The business had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion.

Institutional Investors Weigh In On Dr. Reddy's Laboratories

Institutional investors and hedge funds have recently bought and sold shares of the business. Costello Asset Management INC bought a new position in shares of Dr. Reddy's Laboratories during the first quarter valued at approximately $26,000. EverSource Wealth Advisors LLC increased its position in Dr. Reddy's Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after buying an additional 1,507 shares during the period. Glass Jacobson Investment Advisors llc lifted its stake in Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after buying an additional 1,600 shares during the last quarter. POM Investment Strategies LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after acquiring an additional 1,820 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Dr. Reddy's Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after acquiring an additional 2,093 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.